Asset Details
Do you wish to reserve the book?
Prognostic implication of dynamic platelet count in lung cancer patients with thrombocytosis: a retrospective analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prognostic implication of dynamic platelet count in lung cancer patients with thrombocytosis: a retrospective analysis
Do you wish to request the book?
Prognostic implication of dynamic platelet count in lung cancer patients with thrombocytosis: a retrospective analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prognostic implication of dynamic platelet count in lung cancer patients with thrombocytosis: a retrospective analysis
2025
Overview
Thrombocytosis is associated with poor prognosis in lung cancer patients. However, no studies have further assessed the effect of platelet-related parameters on the prognosis among lung cancer patients with thrombocytosis.
Between 2020 and 2021, lung cancer patients with a platelet count ≥ 300 *10
/L or normal count were retrospectively reviewed. Potential prognostic factors were identified using univariate and multivariate accelerate failure time (AFT) model. Kaplan-Meier method and log-rank test were used to compare survival outcome.
Among patients with thrombocytosis (
= 148), time point of platelet elevation, platelet distribution width (PDW), platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) did not significantly impact first-line progression-free survival (PFS). Compared to patients whose platelet count normalized after treatment, patients with sustained platelet elevation exhibited a worst PFS (β = - 1.291,
< 0.001), and although patients with fluctuant platelet elevation had worse PFS (β = - 0.358,
= 0.054), the difference was not statistically significant. Additionally, mean platelet volume (MPV) (β = 0.319,
= 0.008) and D-dimer (β = - 0.046,
= 0.025) were also factors affecting first-line PFS.
Among platelet-related parameters, besides MPV and D-dimer, the dynamic pattern of platelet count serves as a prognostic marker in lung cancer patients with thrombocytosis.
